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Background:! The! gold! standard! endpoint! in! randomized! clinical! trials! in!metastatic!





Methods:! Eligible! trials! accrued!HER2+!metastatic! breast! cancer! patients! in! 1992Q
2008.! A! correlation! approach! was! used:! at! the! individual! level,! to! estimate! the!
association! between! investigatorQassessed! progressionQfree! and! overall! survival!
using! a! bivariate!model! and! at! the! trial! level,! to! estimate! the! association! between!
treatment!effects!on!progressionQfree!and!overall!survival.!Correlation!values!close!to!
1.0!would!indicate!strong!surrogacy.!!
Results:! We! identified! 2545! eligible! patients! in! 13! randomized! trials! testing!
trastuzumab!or!lapatinib.!We!collected!individual!patient!data!from!1963!patients!and!
retained!1839!patients! from!9! trials! for!analysis! (7! firstQline! trials).!During! followQup,!
1072! deaths! and! 1462! progression! or! deaths! occurred.! The!median! survival! time!
was! 22! months! (95%! CI! 21Q23!months)! and! the! median! progressionQfree! survival!
was! 5.7! months! (95%! CI! 5.5Q6.1! months).! At! the! individual! level,! the! Spearman!




Conclusions:! In! trials!of!HER2Qtargeted!agents! in!HER2+!metastatic!breast!cancer,!
progressionQfree!survival!moderately!correlates!with!overall!survival!at!the!individual!














Worldwide,! approximately! 1.68! million! new! cases! of! female! breast! cancer! are!
diagnosed!each!year!and!this!rate!is!increasing!globally[1].!Approximately!15Q30%!of!
these!tumors!overexpress!HER2/neu!(human!epidermal!Growth!factor!receptor!type!
2),! which! is! associated! with! aggressive! tumor! behavior! and! poor! prognosis[2Q4].!
Trastuzumab,!a!monoclonal!antibody!directed!against!the!extracellular!domain!of!the!




proportion! of! women! will! experience! a! recurrence! or! progression! of! their! disease,!
suggesting!the!presence!of!de!novo!resistance!or! the!development!of! resistance!to!
trastuzumab.! This! has! led! to! the! pursuit! and! successful! development! of! other!
molecules,!used!alone!or!in!combination!with!trastuzumab!or!chemotherapy:!lapatinib!
(approved!by! the!Food!and!Drug!Administration! (FDA)! in!2007)!and!more! recently,!
pertuzumab!(2012)!and!TrastuzumabQDM1!(2013).!
The!gold!standard!endpoint!for!the!evaluation!of!new!therapies!in!oncology!is!overall!
survival! (OS).!But!OS,! although! simple! to!measure,! easy! to! interpret! and! clinically!
meaningful,! has! the! disadvantage! of! requiring! extended! followQup,! and! of! being!
confounded!by!unrelated!causes!of!death!or!the!successive!lines!of!effective!therapy!
now!available!in!common!solid!tumors.!An!endpoint!that!is!reached!more!rapidly!may!
answer! the! question! posed!by! clinical! trials!more! quickly! and,! potentially,! expedite!
drug! approval.! For! example! in! colorectal! cancer,! diseaseQfree! survival! (DFS)! has!
been!validated!as!a!surrogate!for!OS!in!the!adjuvant!setting[9]!and!progressionQfree!
survival!(PFS)!has!been!validated!as!a!surrogate!for!OS!in!advanced!disease[10].!It!
should! be! noted,! however,! that! surrogate! endpoints!may! be! specific! to! a! class! of!
agents.! In! colorectal! cancer,! DFS! and! PFS! have! only! been! validated! for! firstQline!
fluoropyrimidineQbased!regimens,!and!the!extrapolation!of!surrogacy!to!other!classes!
of!agents!having!substantially!different!mechanisms!of!action!may!not!be!warranted.!!
The! preferred! approach! for! surrogate! endpoint! evaluation! is! the! use! of! individual!
patient! data! (IPD),! the! reference! method! against! which! other! forms! of! systematic!
review! should! be! measured.! Within! this! framework,! a! surrogate! endpoint! may! be!




In! the! advanced! setting,! PFS! has! been! shown! to! be! an! appropriate! surrogate! for!
evaluation!of!chemotherapy!effects!in!several!malignancies,!but!in!metastatic!breast!
cancer!(MBC),!PFS!was!shown!not!to!be!a!valid!surrogate!for!overall!survival!when!
reanalyzing! 3,953! patients! in! 11! trials! that! compared! an! anthracycline! (alone! or! in!
combination)! with! a! taxane! (alone! or! in! combination! with! an! anthracycline)[11].! A!
literatureQbased! study! of! 67! trials! in! MBC! of! various! chemotherapy! regimens! also!
suggested! an! insufficiently! high! correlation! [18].! However,! a! more! recent! metaQ
analysis! of! the! literature! found! a! stronger! correlation! between! treatment! effects! in!
trials!of!HER2Qpositive!MBC,!as!compared!to!the!HER2Qnegative!population!([19])!so!
that!further!evaluation!of!PFS!as!a!surrogate!endpoint!of!OS!is!warranted.!This!study,!








We! assessed! the! endpoints! according! to! the! preplanned! objective! of! PFS! as! a!
surrogate!for!OS!in!MBC!patients!in!trials!studying!the!effect!of!antiQHER2!treatments!
and! wrote! a! study! protocol! (available! upon! request),! which! was! approved! by! the!
medical! ethics! committee! of! Jules! Bordet! Institute.! Briefly,! a! previously! conducted!
electronic! literature! search[20]! was! updated! using! PubMed! Qusing! terms!
‘trastuzumab’,! ‘Herceptin’! ‘lapatinib’,! ‘Tykerb’,! ‘pertuzumab’,! ‘neratinib’,!
‘TrastuzumabQDM1’!and!the!exploded!MeSH!term!‘breast!neoplasms’!and!search!line!
[(breast!or!mammary)!and!(cancer*!or!tumour*!or!tumor*!or!neoplas*!or!metastas*!or!
carcinoma)]Q,! clinicaltrials.gov! and! conference! proceedings! in! April! 2011.! Eligible!
publications! consisted! of! randomized! controlled! trials! (phase! II! or! III)! that! accrued!
HER2+! MBC! ! patients! in! 1992Q2008.! At! least! one! of! the! study! arms! had! to!
investigate! a! HER2Qtargeted! agent.! A! collaboration! was! sought! with! industrial!






radiological! progression,! or! death.! Patients! who! had! no! documented! evidence! of!
events!were!censored!at!the!date!of!last!followQup.!OS!was!defined!as!the!time!from!
randomization!to!death,!irrespective!of!cause.!
A! correlation! approach! was! used:! at! the! individual! level,! the! rank! correlation!
coefficient! ρ! between! distributions! of! PFS! and! OS! was! assessed! with! a! bivariate!
survival!model! that! takes!censoring! into!account! (Hougaard!copula)[21]Z!at! the! trial!
level,! the!correlation!between! treatment!effects! (log!hazard! ratios)!on!PFS!and!OS!
were!quantified!through!a! linear!regression!model,!weighted!by!trial!size.!Treatment!
effects!were!estimated!by!Cox!regression!and!by!the!copula!model.!
The! squared! correlation! coefficients! or! coefficients! of! determination—ie,! ρ2! at! the!
individual!level!and!R2!at!the!trial!level—were!calculated!to!investigate!the!amount!of!
variation! explained! by! the! surrogate.! The! candidate! surrogate! endpoints! were!
deemed!acceptable!only!if!both!correlation!coefficients!were!close!to!1·00.!!We!used!
a! leaveQoneQtrial! out! strategy! to! study! the! sensitivity! of! the! trialQlevel! squared!
correlation!when!leaving!each!trial!out!once.!!
The! surrogate! threshold! effect!was! calculated! as! the!minimum! treatment! effect! on!
the! surrogate! that! would! be! necessary! to! predict! a! nonQzero! effect! on! OS[22].! A!
future! trial! would! require! an! upper! limit! of! the! confidence! interval! (CI)! for! the!
estimated! surrogate! treatment! effect! to! fall! below! the! surrogate! threshold! effect! to!
predict!a!nonQzero!effect!on!OS.!
TheKaplanQMeier!method!was!used! to!construct!survival!curves.!Median! followQup!











progression[30]! leading! to! a! total! of! 1839! patients! included! in! 8! trials! that! were!
retained!for!analysis.!Details!of!the!treatment!arms!evaluated!are!provided!in!Table!1.!
One! trial! was! a! fourQarm! trial! leading! to! a! total! of! 2! treatment! comparisons! for!
targeted!HER2Qtreatments.!We!will! denote! the! total! of! 9! treatment! comparisons!as!
‘trials’! from!now!on,!of!which!6! tested! trastuzumab!and!3! lapatinib.!The!majority!of!
trials! were! conducted! in! the! firstQline! setting! (7! out! of! 9! trials,! 1198! patients).! The!
description!of!the!patients!included!in!the!9!trials!is!provided!in!Supplementary!table!
1.! A! small! majority! (55%! in! control,! 56%! in! antiQHER2! arm)! of! patients! were! ERQ
negative.!Of!note,!552!patients!(30%)!had!been!previously!exposed!to!trastuzumab!
before! inclusion! in! the! trials,! while! the! majority! of! patients! had! been! exposed! to!
chemotherapy.!
The!median!followQup!for!OS!and!PFS!were!given!by!respectively!33!months!(95%!CI!
32Q34! months)! and! 28! months! (95%! CI! 26Q32! months).! During! followQup,! 1072!




arm! and! 30%! (95%! CI! 28Q34%)! in! the! antiQHER2! agent! armZ! while! 2Qyear! OS!
probability!estimates!were!42%!(95%!CI!39Q46%)!in!the!control!arm!and!51%!(95%!
CI!47Q54%)!in!the!antiQHER2!agent!arm.!
At! the! individual! level,!PFS!was!moderately!correlated!with!OS!(Spearman!ρ=0.67,!
95%! CI! 0.67Q0.68,! or! equivalently! an! R2! value! of! 0.45,! 95%! CI! 0.44Q0.45).! In! an!
exploratory!analysis,!we!restricted!the!data!to!those!583!patients!included!in!firstQline!
trials! before! 1998,! the! year! of! FDA! approval! of! trastuzumab.! The! individual! level!
correlation!was!estimated!to!be!the!same!(ρ=0.67,!95%!CI!0.67Q0.68).!!
At! the! trial! level,! treatment! effects! on! PFS! correlated! moderately! with! treatments!






horizontal! line! at! hazard! ratio! of! OS! equal! to! 1! and! the! upper! bound! of! the! 95%!
prediction!interval!of!the!regression!line).!The!slope!of!the!weighed!linear!regression!
equation!is!estimated!by!0.44!(standard!error!0.16)!and!the!intercept!by!0.04!(0.08),!
so! that! estimated! treatment! effects! on!OS! are! largely! attenuated.!When! using! the!
treatment!effects!as!estimated!by!the!copula!model,!the!weighted!R2!was!estimated!
by!R2=0.65!(95%!CI!0.40!to!0.90).!!
In! the! leaveQoneQout!analysis! in!which!each!trial!was! left!out!once,! the!trialQlevel!R2!
values!were!very!sensitive! to! the!exclusion!of!single! trials!and!ranged! from!0.05! to!
0.71,! with! a! median! R2! of! 0.53.! Some! additional! unplanned! exploratory! subgroup!
analyses! restricting! the!data! to! the!set!of! firstQline! trials,! to!ERQpositive!patients,! to!








revealed!mixed! results.! The! interpretation! of! the! findings! of! 3! studies! is! limited! as!
they! extracted! data! from! published! literature[18,! 19,! 31].! In! contrast,! one! study!
evaluated! individual! patient! data! from! 3953! patients! included! in! 11! randomized!
clinical!trials!that!compared!an!anthracycline!with!a!taxane[11].!PFS!was!shown!not!
to! be! a! valid! surrogate! for! OS! (individual! level! ρ=0.69! and! trialQlevel! squared!
correlation! R2=0.23).!However,! it! is! known! that! a! surrogate! endpoint! needs! to! be!
evaluated!for!classes!of!drugs!since!the!mechanism!of!action!can!be!different.!!
In!this!study!we!explored!whether!in!a!more!biologically!homogenous!defined!group!
of! patients! (HER2+)! the! surrogacy!of!PFS! for!OS!may!be!higher! for! targeted!antiQ
HER2! cancer! therapies.! Using! the! gold! standard! method! to! study! trialQlevel!
surrogacy! Q! i.e.! through! collection! of! individual! patient! dataQ! we! included! 1839!
patients! from!9! trials! in! the!analyses.!PFS!was!shown! to!be!moderately!correlated!
with!OS!at! the! individual! level! (Spearman!correlation!ρ=0.67,!95%!CI!0.67! to!0.68)!
and! treatments! effects! (log! hazard! ratios)! on! PFS! correlated! moderately! with!
treatment! effects! on! OS! (R2=0.51,! 95%! CI! 0.22! to! 0.81).! Of! note,! our! estimated!
individual!level!correlation!(0.67)!was!almost!identical!to!the!estimated!individual!level!
correlation! in! the! metastatic! trials! of! anthracycline! vs.! taxane! (0.69).! As! far! as!
treatment! effects!were! concerned,! to! the!best! of! our! knowledge! there! is! no! formal!
consensus! on! the! minimum! trialQlevel! R2! value! needed! to! validate! a! surrogate!
endpoint!and!several!authors!have!used!different!cutQoffs!(from!0.60!([32,!33])!to!0.72!





HER2+!MBC! could! be! related! to! the! crossover! that! was! allowed! in! several! of! the!
included!trials,!the!administration!of!2nd!or!3thQline!treatments!and!the!relatively!long!
postQprogression!time[36],!a!feature!not!common!to!the!studies!of!other!malignancies!
where! PFS! has! been! validated! as! surrogate! for! OS! (i.e.! advanced! colorectal!
cancer[10],! locally! advanced! lung! cancer[13],! locally! advanced! head! and! neck!
cancer[14]).! In! the! trials! included! in! the! current! study,! only! scarce! information! on!
crossover!was!collected!excluding!a!potential! trialQlevel!evaluation! taking!crossover!
into!account.!Just!as!in!colorectal!cancer!where!several!strategy!trials!have!already!
been!conducted[37],!the!objective!of!future!trials! in!MBC!could!consist! in! identifying!
the!optimal! treatment!sequence!across! lines!of! therapy! instead!of! the!best! firstQline!




in! the! firstQline! setting! (n=2447),! adding! bevacizumab! to! standard! chemotherapy!
prolonged! PFS! (HR=0.64,! 95%!CI! 0.57Q0.71)! but! did! not! significantly! improve!OS!
(HR=0.97,! 95%!CI! 0.86–1.08)[38].! In! 2011,! the! FDA!withdrew! its! authorization! for!
bevacizumab! in! MBC! after! the! initial! accelerated! approval! of! 2008.! The! use! of!
surrogate! endpoints! in! trials! should! not! be! used! as! an! excuse! for! not! performing!
longQterm!followQup,!which!is!necessary!to!control!unexpected!adverse!reactions!and!






but! also! a! couple! of! studies!with! lapatinib! or! trastuzumab)[39Q42].! These!were! not!
eligible!when!our!protocol!was!setQup!and!accrued!patients!after!our!cutQoff!date!of!
2008.! It!may! thus!be!of! interest! to!update! the!current!analysis! in!a! future! research!
collaboration.!However,!it!seems!rather!unlikely!that!the!degree!of!surrogacy!of!PFS!
for! OS! would! increase! because! there! likely! were! more! effective! 2ndQand! 3thQline!
options!available! in! the!recent! trials!as!compared!to! the!historical!ones.!The!recent!
trials! may! potentially! have! more! precise! recordings! of! treatments! received! after!
progression! for! fineQtuned!analyses!of!crossover,!although! it! is!still! not! the!norm! in!
oncology!clinical!trials!to!systematically!collect!this!information.!!
In!summary,!the!current!findings!provide!only!modest!support!for!considering!PFS!as!
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